Honduras vs Kazakhstan: Average cost of multi drug-resistant tuberculosis treatment
Honduras
3,743 constant 2022 US$
in 2024
Kazakhstan
3,398 constant 2022 US$
in 2023
Honduras rank
11th
Kazakhstan rank
13th
Average cost of multi drug-resistant tuberculosis treatment over time
- Honduras
- Kazakhstan
How they compare
Honduras currently reports 3,743 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan, a difference of 345 constant 2022 US$.
That makes Honduras's figure about 1.1 times Kazakhstan's.
Across all 7 years both countries report, Kazakhstan has been ahead every year.
Honduras ranks 11th and Kazakhstan ranks 13th of 92 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Honduras | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,711 constant 2022 US$ | 3,280 constant 2022 US$ | 1,569 constant 2022 US$ | Kazakhstan |
| 2020s | 1,428 constant 2022 US$ | 2,932 constant 2022 US$ | 1,504 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Honduras or Kazakhstan?
- Honduras, at 3,743 constant 2022 US$ against 3,398 constant 2022 US$ in Kazakhstan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Honduras and Kazakhstan?
- 345 constant 2022 US$, with Honduras ahead.
- How many years of comparable data are there for Honduras and Kazakhstan?
- 7 years are reported by both, from 2017 to 2023.
- How do Honduras and Kazakhstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Honduras ranks 11th and Kazakhstan ranks 13th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.